At the news
? NEUTRALIMPACT 5/10 8-K filed Nov 9, 2026 at 16:00 ET
Xenon reported Q3 2026 results with a net loss of $110.4M, wider than the $90.9M loss in Q3 2025, driven by higher R&D spending. The key catalyst is the NDA submission for azetukalner in focal seizures and the upcoming X-NOVA2 MDD topline data readout in December 2026, though a voluntary pause on new enrollment in MDD/BPD studies introduces uncertainty.
- NDA for azetukalner in focal seizures submitted to FDA in September 2026
- Phase 3 X-NOVA2 MDD study enrollment completed; topline data expected December 2026
- Voluntary pause on new patient enrollment in ongoing Phase 3 MDD and BPD studies announced in September 2026
- Positive Phase 1 data for XEN1701 (NaV1.7) and XEN1120 (KV7) pain programs; Phase 2 POC studies expected H1 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access